Remove 2028 Remove Food and Drug Administration Remove Sales
article thumbnail

Alimera Sciences buys US rights to EyePoint’s Yutiq

Pharmaceutical Technology

It received approval from the US Food and Drug Administration in October 2018. EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. will be paid in equal quarterly instalments in 2024.

article thumbnail

Astellas to accelerate ocular disease treatments with $5.9 billion acquisition

European Pharmaceutical Review

Avacincaptad pegol is forecasted to achieve sales of $1.09 billion in 2028, according to GlobalData’s Pharma Intelligence Center. The acquisition “has the potential to benefit patients worldwide suffering from blinding retinal diseases, including GA,” acknowledged Dr Pravin U Dugel, President of Iveric Bio.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MSD secures full approval for Keytruda’s use in MSI-high solid tumours

Pharmaceutical Technology

The drug is approved in several indications, including advanced melanoma, metastatic non-small cell lung cancer (NSCLC), and relapsed classical Hodgkin lymphoma (cHL). In 2022, the company reported Keytuda sales of $20.9 As per GlobalData’s consensus forecasts, the drug is estimated to yield global sales of $34.79

article thumbnail

An increasing impact of BCMA-targeting biologics in multiple myeloma

Pharmaceutical Technology

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

article thumbnail

Viatris to acquire Oyster Point and Famy Life Sciences

Pharmaceutical Technology

Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year. These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. Famy Life Sciences has an ophthalmology portfolio that complements Viatris.

article thumbnail

More big wins for the AstraZeneca-Daiichi Sankyo collaboration

Pharmaceutical Technology

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.

article thumbnail

Acute lymphocytic leukaemia leads in cell therapy clinical development

Pharmaceutical Technology

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Leads 52